Sharma East India Hospitals and Medical Research Ltd has closed its trading window for designated persons effective July 1, 2026, in preparation for the release of its standalone unaudited financial results for the quarter ended June 30, 2026. This measure is implemented to prevent insider trading and ensure market integrity during the sensitive period surrounding financial disclosures. The restriction applies to all individuals with access to unpublished price-sensitive information (UPSI).

The closure follows the regulations outlined in the BSE Circular dated April 2, 2019 (Ref No: LIST/COMP/01/2019-20). The company communicated this decision to the Department of Corporate Service at BSE Limited to formally record the compliance measure. The trading window will remain shut until the financial results are made public.

According to the filing, the window is scheduled to reopen 48 hours after the announcement of the standalone unaudited financial results for the quarter ended June 30, 2026, becomes generally available. This interval allows the market to absorb the information before designated persons resume trading activities.

The intimation was signed by Bhawana Sharma, the Company Secretary and Compliance Officer, on behalf of the company. The communication was addressed to the BSE Limited office in Mumbai, confirming the adherence to regulatory protocols.

Sharma East India Hospitals and Medical Research Limited reported a net profit of ₹124.27 lakh for the financial year ended March 31, 2026, compared to ₹124.43 lakh in the previous year. Total income from operations for the year rose to ₹3,608.91 lakh from ₹3,018.59 lakh in the corresponding period of the previous year. The company's earnings per share (EPS) for the year stood at ₹3.78, marginally lower than the ₹3.79 recorded in the prior year.

For the quarter ended March 31, 2026, the company recorded a net profit of ₹42.92 lakh, an increase from ₹36.69 lakh in the same quarter of the previous year. Total income from operations for the quarter stood at ₹748.71 lakh, up from ₹621.78 lakh in the corresponding quarter of the previous year. The basic and diluted EPS for the quarter was reported at ₹1.31.

The statutory auditors of the company conducted the audit of the financial results for the year ended March 31, 2026, as required under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Audit Committee reviewed the results, which were subsequently approved by the Board of Directors at their meeting held on May 30, 2026.

Financial Performance Summary

The following table outlines the key financial metrics for the quarter and year ended March 31, 2026:

The figures for the previous period or year have been regrouped, rearranged, and/or recast wherever necessary. The detailed format of the quarterly and yearly financial results is available on the company's website and the BSE website.